[{"indications": "Indications\u00a0androgenetic alopecia in men; benign\r\nprostatic hyperplasia (section 6.4.2)", "name": "FINASTERIDE - ANDROGENETIC ALOPECIA", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.9 Shampoos and other preparations for scalp and hair conditions", "Androgenetic alopecia", "FINASTERIDE"], "cautions": "Cautions\u00a0section 6.4.2", "side-effects": "Side-effects\u00a0section 6.4.2", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106493.htm", "doses": ["By mouth 1\u00a0mg daily"]}, {"indications": "Indications\u00a0benign prostatic hyperplasia;\r\nmale-pattern baldness in men (section 13.9)", "name": "FINASTERIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.2 Male sex hormones and antagonists", "Anti-androgens", "Dutasteride and finasteride"], "cautions": "Cautions\u00a0\n(From Dutasteride and finasteride: British National Formulary)\nCautions\u00a0Dutasteride and finasteride decrease serum concentration of prostate cancer markers such as prostate-specific antigen; reference values may need adjustment. Both dutasteride and finasteride are excreted in semen and use of a condom is recommended if sexual partner is pregnant or likely to become pregnant. Women of childbearing potential should avoid handling crushed or broken tablets of finasteride and leaking capsules of dutasteride.; also obstructive\r\nuropathyMale breast cancer\u00a0Cases of male breast cancer\r\nhave been reported. Patients or their carers should be\r\ntold to promptly report to their doctor any changes in breast tissue\r\nsuch as lumps, pain, or nipple discharge", "side-effects": "Side-effects\u00a0see notes above; also testicular pain, hypersensitivity\r\nreactions (including lip and face swelling, pruritus and rash); male\r\nbreast cancer also reported (see Cautions above)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4376.htm", "doses": ["5\u00a0mg daily, review treatment at 3\u20136 months and then every\r\n6\u201312 months (may require several months\u2019 treatment before benefit\r\nis obtained)"]}, {"indications": "Indications\u00a0benign prostatic hyperplasia;\r\nmale-pattern baldness in men (section 13.9)", "name": "FINASTERIDE - DUTASTERIDE AND FINASTERIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.2 Male sex hormones and antagonists", "Anti-androgens", "Dutasteride and finasteride"], "cautions": "Cautions\u00a0\n(From Dutasteride and finasteride: British National Formulary)\nCautions\u00a0Dutasteride and finasteride decrease serum concentration of prostate cancer markers such as prostate-specific antigen; reference values may need adjustment. Both dutasteride and finasteride are excreted in semen and use of a condom is recommended if sexual partner is pregnant or likely to become pregnant. Women of childbearing potential should avoid handling crushed or broken tablets of finasteride and leaking capsules of dutasteride.; also obstructive\r\nuropathyMale breast cancer\u00a0Cases of male breast cancer\r\nhave been reported. Patients or their carers should be\r\ntold to promptly report to their doctor any changes in breast tissue\r\nsuch as lumps, pain, or nipple discharge", "side-effects": "Side-effects\u00a0see notes above; also testicular pain, hypersensitivity\r\nreactions (including lip and face swelling, pruritus and rash); male\r\nbreast cancer also reported (see Cautions above)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4376.htm", "doses": ["5\u00a0mg daily, review treatment at 3\u20136 months and then every\r\n6\u201312 months (may require several months\u2019 treatment before benefit\r\nis obtained)"]}]